

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**绿竹生物**  
LUZHU BIOTECH

**Beijing Luzhu Biotechnology Co., Ltd.**  
**北京綠竹生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2480)**

**VOLUNTARY ANNOUNCEMENT  
INITIATION OF PHASE III CLINICAL TRIAL AND  
COMPLETION OF ENROLLMENT OF FIRST GROUP OF  
SUBJECTS FOR LZ901 IN THE PRC**

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, the multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial of LZ901, the core product of the Group, has been initiated on September 26, 2023 in the People’s Republic of China (the “**PRC**”), to evaluate the efficacy and safety profile of LZ901 for the prevention of herpes zoster in adults aged 40 years and older, with the first group of subjects having been enrolled as of the date of this announcement. The study will be conducted in four provinces including Jiangsu, Shandong, Hubei and Shanxi, with a planned enrollment of approximately 26,000 healthy subjects aged 40 years and older.

The Phase I and Phase II clinical trials of LZ901 in China were completed in April 2022 and May 2023, respectively. The safety and immunogenicity analysis results obtained demonstrated that LZ901 has favorable safety profile and immunogenicity profile.

In addition, the Group has newly secured registration of its invention patent for LZ901 in Japan. As of the date of this announcement, the invention patent for LZ901 has been granted in the PRC, Russia and Japan.

LZ901 targets to prevent shingles in adults aged 40 years and older. Shingles is a viral infection that causes a painful rash that can materially and negatively impact quality of life. Shingles can reoccur, with the recurrence rate increasing with age. There are currently no specific drugs that can cure shingles and vaccination is the only way to protect people against shingles and its complications, which is also the cost-effective way to prevent the occurrence of the diseases.

## **ABOUT LZ901**

LZ901 is a recombinant herpes zoster vaccine candidate independently developed by the Group, and is the core product of the Group. It is developed based on the varicella-zoster virus (“VZV”) glycoprotein E-fragment crystallizable region, and has a tetrameric molecular structure to prevent shingles caused by VZV. LZ901 is designed on the basis of making full use of the mechanism of the human immune system for processing foreign antigens, and prevents the occurrence of herpes zoster and related complications caused by herpes zoster, including postherpetic neuralgia.

## **ABOUT THE COMPANY**

The Company is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Company has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Company to develop its recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability.

**Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that LZ901 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Beijing Luzhu Biotechnology Co., Ltd.**  
**Mr. KONG Jian**  
*Chairman and Executive Director*

Hong Kong, September 28, 2023

*As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshi and Ms. HOU Aijun as independent non-executive Directors.*